Free Trial
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals logo
$4.10 -0.07 (-1.68%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.04 -0.06 (-1.46%)
As of 08/1/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Key Stats

Today's Range
$3.96
$4.12
50-Day Range
$3.49
$4.75
52-Week Range
$2.54
$10.00
Volume
604,705 shs
Average Volume
436,656 shs
Market Capitalization
$279.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Corvus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

CRVS MarketRank™: 

Corvus Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 690th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Corvus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corvus Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corvus Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corvus Pharmaceuticals has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Corvus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Corvus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corvus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Corvus Pharmaceuticals this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,893,541.00 in company stock.

  • Percentage Held by Insiders

    28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corvus Pharmaceuticals' insider trading history.
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

Digital Dollar Alert: Protect Your Wealth Before It’s Too Late
134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.
3 Penny Stocks Wall Street Sees With 243% Upside
See More Headlines

CRVS Stock Analysis - Frequently Asked Questions

Corvus Pharmaceuticals' stock was trading at $5.35 at the start of the year. Since then, CRVS shares have decreased by 23.4% and is now trading at $4.10.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13).
Read the conference call transcript
.

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals' top institutional investors include Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.25%) and Masso Torrence Wealth Management Inc. (0.07%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais.
View institutional ownership trends
.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRVS
CIK
1626971
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$11.00
Potential Upside/Downside
+265.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.29 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.04%
Return on Assets
-13.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.90
Quick Ratio
4.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
8.04

Miscellaneous

Outstanding Shares
68,170,000
Free Float
48,741,000
Market Cap
$279.50 million
Optionable
Optionable
Beta
0.42

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CRVS) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners